December II, 2023

At 12 months, patients in the experimental arm showed OS rates of 14.4% compared with 11.1% for patients receiving chemotherapy alone in the phase 3, open-label CheckMate649 study.

Rucaparib showed a significant improvement in progression-free survival compared with docetaxel in metastatic castration- resistant prostate cancer.

The landmark study, KEYNOTE-564, compared pembrolizumab vs placebo in patients with clear cell renal cell carcinoma who were at high risk for recurrence after nephrectomy.

The ECHELON-2 study compared brentuximab vedotin plus cyclophosphamide, doxorubicin, and prednisone chemotherapy with the standard-of-care cyclophosphamide, doxorubicin, vincristine, and prednisone regimen for CD30- positive T-cell lymphoma.

Findings from the MOMENTUM study evaluating momelotinib demonstrated symptom, spleen, and anemia benefits in myelofibrosis compared with danazol in previously treated patients with anemia and intermediate- or high-risk myelofibrosis.

Sarah B. Goldberg, MD, MPH, presented these findings to demonstrate the effective time to use immuno-oncology combination therapy during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow.

In a presentation during the 41st Annual Chemotherapy Foundation Symposium Innovative Cancer Therapy for Tomorrow conference, Jessica Lin, MD, discussed the landscape of targeted therapies in driver mutations in non–small cell lung cancer.

As clinicians navigate the array of available antibody-drug conjugates for HER2-negative metastatic breast cancer, Joshua Z. Drago, MD, MS, emphasizes the importance of considering various factors in therapy selection and sequencing.

Trastuzumab deruxtecan emerges as a superior second-line option for HER2-positive metastatic breast cancer, with a fourfold increase in median progression-free survival vs trastuzumab emtansine, as reported in the DESTINY-Breast03 trial.

New treatments, including luspatercept-aamt, have been added to the treatment algorithm of patients with low-risk myelodysplastic syndrome in 2020.

According to John M. Burke, MD, it is hard to imagine that results presented at ESMO in the urothelial cancer space will not lead to the complete replacement of conventional chemotherapy as the standard first-line treatment.